After Sinovac, China’s Anhui COVID-19 Vaccine Also Tests …

loading…

BANDUNGVaccine for COVID-19 from China, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. It is certain that it will conduct phase 3 clinical trials in Indonesia in early March 2021. This vaccine will be the second Covid vaccine after Sinovac which conducted phase 3 clinical trials in Indonesia.

Confirmed that the clinical trial of the COVID-19 vaccine will be carried out, the main researcher of the phase III clinical trial of the COVID-19 Anhui vaccine, dr. Rodman Tarigan, Sp.A (K), M.Kes. According to him, clinical trials will begin in early March 2021. This phase III clinical trial will involve 4,000 volunteers.

Also read: Gegara Sabu, this beautiful police chief was detained by the West Java Police, this is his figure

Anhui Zhifei Longcom Biopharmaceutical is a vaccine manufacturer from China. One of the products that has been produced is the meningitis vaccine that has been used for Haj and Umrah pilgrims in Indonesia.

“We are targeting non-health volunteers,” said Rodman in the official statement of Unpad Public Relations, Thursday (18/2/2021).

In contrast to the type of COVID-19 vaccine developed by Sinovac, Anhui is developing a recombinant vaccine type or protein sub unit. This means that the vaccine platform is taken from the glycoprotein spike or a small part of the virus that triggers immunity when injected into the human body. This is different from the type of Sinovac vaccine which is taken from a virus that is killed.

Also read: Once splashed on citizens, this turned out to be the mystery of Risa Saraswati’s orange box

In theory, said Rodman, recombinant vaccines cause a longer immune system than a killed virus. For example, the Hepatitis B recombinant vaccine. Based on the results of the study, injection of 3 times the vaccine will provide longer immunity.

“In theory, recombinant vaccines can last longer and provide longer protection, maybe up to 2 years. However, this theory must be proven by clinical trials, “said Rodman.

Anhui’s COVID-19 recombinant vaccine itself has undergone phase I clinical trials involving 50 research subjects and phase II clinical trials with 900 research subjects. The results of these two clinical trials are claimed to be safe and provide high immunity.

For phase III clinical trials, Unpad received direct trust from PT. BCHT Biotechnology Indonesia, as a foreign investment company from Anhui as an Indonesian university that will carry out phase III clinical trial research. This means, Unpad has twice been trusted as a phase III clinical testing college for the COVID-19 vaccine

(msd)

.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.